Ventus Therapeutics U.S., Inc.
🇺🇸United States
A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson's Disease
- First Posted Date
- 2025-02-12
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Ventus Therapeutics U.S., Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT06822517
- Locations
- 🇺🇸
Investigative Site, Spokane, Washington, United States
© Copyright 2025. All Rights Reserved by MedPath